Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2024-04-15 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
公司章程修改对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table of amendments to the Articles of Association (公司章程) of a listed company, including references to governance structures, shareholder rights, board responsibilities, and compliance with regulatory guidelines such as those from the China Securities Regulatory Commission and Shenzhen Stock Exchange. It extensively discusses corporate governance, board and management duties, shareholder meetings, voting rights, and dividend policies. There is no indication that this is an annual report, financial statement, earnings release, or any other financial report. Instead, it is a governance document focused on the company's internal rules and corporate governance practices. Therefore, the document fits best under the category of Governance Information (CGR). The document length (15,000 characters) and content confirm it is the actual governance document, not just an announcement or summary.
2024-04-15 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the decision to use idle funds for cash management, including details on the investment purpose, amount, risk control, and approvals. It is a formal disclosure of a financing-related decision but does not contain financial statements or results. It is not a full financial report, earnings release, or management discussion. The document is relatively short (1834 characters) and serves as a regulatory announcement about capital use and management authorization. Therefore, it fits best under Capital/Financing Update (CAP).
2024-04-15 Chinese
2023年度会计师事务所履职情况评估报告及审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm and the audit committee's supervision of the accounting firm for the year 2023. It discusses the audit firm's qualifications, the audit process, and the audit committee's oversight activities. It references the audit report issued by the accounting firm but does not contain the full audit report or detailed financial statements itself. The document is a standalone report focused on audit performance and oversight, which fits the definition of an Audit Report / Information (AR). The document length is 1765 characters, which is short but contains substantive content about audit evaluation rather than just an announcement or certification. Therefore, it is classified as AR with high confidence.
2024-04-15 Chinese
董事会对独董独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board regarding the independence assessment of independent directors, referencing regulatory rules about independent directors and their independence. It is not a financial report, earnings release, or management discussion. It is a board/management related announcement about director independence evaluation, which fits best under Board/Management Information (MANG). The document is short and specific to board matters, not a general regulatory filing or report publication announcement.
2024-04-15 Chinese
董事会提名委员会议事规则
Governance Information Classification · 95% confidence The document is titled '董事会提名委员会议事规则' which translates to 'Board Nomination Committee Meeting Rules' for Xiamen Aide Biomedical Technology Co., Ltd. It details the structure, responsibilities, meeting procedures, and governance rules of the board nomination committee. There is no financial data, no mention of financial results, no voting results, no legal proceedings, no capital changes, and no report publication announcements. The content focuses on governance practices related to board nominations and committee operations. Therefore, this document fits best under Governance Information (CGR). The document length is 3379 characters, which is sufficient for a detailed governance document but not a full financial report. Hence, the classification is CGR with high confidence.
2024-04-15 Chinese
独立董事2023年度述职报告（王恩华）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" for Xiamen Aide Biomedical Technology Co., Ltd. It is a detailed report by an independent director about their duties, attendance at board and committee meetings, opinions on company matters, communication with auditors, and oversight activities during the year 2023. The content focuses on the director's role, governance, and compliance with laws and regulations, including references to annual and quarterly reports but does not contain financial statements or earnings data itself. It is a formal report on board/management activities and director duties rather than a financial report or announcement. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 3887 characters, which is sufficient for a detailed report but not a full annual report or financial statement. No indication that this is a certification or a brief announcement. Hence, classification is MANG with high confidence.
2024-04-15 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.